274 related articles for article (PubMed ID: 19472310)
21. Hepatitis B virus X gene and hepatocarcinogenesis.
Ng SA; Lee C
J Gastroenterol; 2011 Aug; 46(8):974-90. PubMed ID: 21647825
[TBL] [Abstract][Full Text] [Related]
22. Integration of the hepatitis B virus X fragment in hepatocellular carcinoma and its effects on the expression of multiple molecules: a key to the cell cycle and apoptosis.
Peng Z; Zhang Y; Gu W; Wang Z; Li D; Zhang F; Qiu G; Xie K
Int J Oncol; 2005 Feb; 26(2):467-73. PubMed ID: 15645132
[TBL] [Abstract][Full Text] [Related]
23. Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis.
Pang R; Lee TK; Poon RT; Fan ST; Wong KB; Kwong YL; Tse E
Gastroenterology; 2007 Mar; 132(3):1088-103. PubMed ID: 17383430
[TBL] [Abstract][Full Text] [Related]
24. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.
Zhang C; Wang X; Fang D; Xu P; Mo X; Hu C; Abdelatty A; Wang M; Xu H; Sun Q; Zhou G; She J; Xia J; Hui KM; Xia H
Theranostics; 2021; 11(5):2108-2122. PubMed ID: 33500714
[No Abstract] [Full Text] [Related]
25. Hepatitis B virus X protein induces EpCAM expression via active DNA demethylation directed by RelA in complex with EZH2 and TET2.
Fan H; Zhang H; Pascuzzi PE; Andrisani O
Oncogene; 2016 Feb; 35(6):715-26. PubMed ID: 25893293
[TBL] [Abstract][Full Text] [Related]
26. HBx protein-mediated ATOH1 downregulation suppresses ARID2 expression and promotes hepatocellular carcinoma.
Gao Q; Wang K; Chen K; Liang L; Zheng Y; Zhang Y; Xiang J; Tang N
Cancer Sci; 2017 Jul; 108(7):1328-1337. PubMed ID: 28498550
[TBL] [Abstract][Full Text] [Related]
27. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
28. Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein.
Arzumanyan A; Sambandam V; Clayton MM; Choi SS; Xie G; Diehl AM; Yu DY; Feitelson MA
Cancer Res; 2012 Nov; 72(22):5912-20. PubMed ID: 22986746
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
[TBL] [Abstract][Full Text] [Related]
30. Truncated HBx-dependent silencing of GAS2 promotes hepatocarcinogenesis through deregulation of cell cycle, senescence and p53-mediated apoptosis.
Zhu R; Mok MT; Kang W; Lau SS; Yip WK; Chen Y; Lai PB; Wong VW; To KF; Sung JJ; Cheng AS; Chan HL
J Pathol; 2015 Sep; 237(1):38-49. PubMed ID: 25925944
[TBL] [Abstract][Full Text] [Related]
31. Role of microRNA-210-3p in hepatitis B virus-related hepatocellular carcinoma.
Morishita A; Fujita K; Iwama H; Chiyo T; Fujihara S; Oura K; Tadokoro T; Mimura S; Nomura T; Tani J; Yoneyama H; Kobayashi K; Kamada H; Guan Y; Nishiyama A; Okano K; Suzuki Y; Himoto T; Shimotohno K; Masaki T
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G401-G409. PubMed ID: 31905024
[TBL] [Abstract][Full Text] [Related]
32. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
Mok WC; Wasser S; Tan T; Lim SG
World J Gastroenterol; 2012 Jul; 18(27):3527-36. PubMed ID: 22826617
[TBL] [Abstract][Full Text] [Related]
33. Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.
Sanhaji M; Louwen F; Zimmer B; Kreis NN; Roth S; Yuan J
Cell Cycle; 2013 May; 12(9):1340-51. PubMed ID: 23574746
[TBL] [Abstract][Full Text] [Related]
34. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
35. Association of p21 with NF-YA suppresses the expression of Polo-like kinase 1 and prevents mitotic death in response to DNA damage.
Lin YC; Chen YN; Lin KF; Wang FF; Chou TY; Chen MY
Cell Death Dis; 2014 Jan; 5(1):e987. PubMed ID: 24407240
[TBL] [Abstract][Full Text] [Related]
36. Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma.
Li Y; Zhao ZG; Luo Y; Cui H; Wang HY; Jia YF; Gao YT
World J Gastroenterol; 2020 Aug; 26(32):4786-4801. PubMed ID: 32921957
[TBL] [Abstract][Full Text] [Related]
37. Influence of miR-520e-mediated MAPK signalling pathway on HBV replication and regulation of hepatocellular carcinoma cells via targeting EphA2.
Tian JH; Liu WD; Zhang ZY; Tang LH; Li D; Tian ZJ; Lin SW; Li YJ
J Viral Hepat; 2019 Apr; 26(4):496-505. PubMed ID: 30521133
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis B virus X protein-induced SH2 domain-containing 5 (SH2D5) expression promotes hepatoma cell growth via an SH2D5-transketolase interaction.
Zheng Y; Ming P; Zhu C; Si Y; Xu S; Chen A; Wang J; Zhang B
J Biol Chem; 2019 Mar; 294(13):4815-4827. PubMed ID: 30659097
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis B virus X protein upregulates alpha-fetoprotein to promote hepatocellular carcinoma by targeting miR-1236 and miR-329.
Zhang C; Liu P; Zhang C
J Cell Biochem; 2020 Mar; 121(3):2489-2499. PubMed ID: 31680299
[TBL] [Abstract][Full Text] [Related]
40. Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis.
Dang S; Zhou J; Chen Y; Chen P; Ji M; Shi B; Yang Q; Hou P
Oncogene; 2019 Jun; 38(24):4804-4819. PubMed ID: 30804458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
